Kadimastem Ltd. Logo

Kadimastem Ltd.

Clinical-stage cell therapy company developing treatments for ALS and diabetes.

KDST | TA

Overview

Corporate Details

ISIN(s):
IL0011284614
LEI:
Country:
Israel
Address:
Pinchas Sapir 3, Weizmann Science Park, 7414003 Nes-Ziona

Description

Kadimastem is a clinical-stage cell therapy company that develops and manufactures "off-the-shelf" allogeneic cell products. The company utilizes a proprietary technology platform to differentiate human pluripotent stem cells into functional cells for treating diseases. Its lead clinical program, AstroRx®, is an astrocyte cell therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Kadimastem is also advancing a preclinical program for Type 1 Diabetes with IsletRx, a product consisting of stem cell-derived pancreatic islet cells intended to restore the body's ability to produce and regulate insulin. The company's focus is on creating regenerative medicine solutions for conditions with high unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-05-02 19:15
Company Presentation May 2021
Russian 42.5 KB
2021-02-18 16:20
IBI Trade Ltd. will cease to operate as a market maker in Kadimastem on March 1…
Hebrew (modern) 184.3 KB
2021-02-17 17:05
Excellence Nessuah will operate as a market maker in the following security: KA…
Hebrew (modern) 208.6 KB
2020-04-25 14:38
Analysis update following financial report
English 1.1 MB
2020-04-25 14:38
Analysis update following financial report
Russian 75.8 KB

Automate Your Workflow. Get a real-time feed of all Kadimastem Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kadimastem Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kadimastem Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ProQR Therapeutics N.V. Logo
Develops RNA therapies for severe genetic disorders using its RNA editing platform.
United States of America
PRQR
Prostatype Genomics AB Logo
Develops a genetic test that assesses prostate cancer aggressiveness to guide treatment.
Sweden
PROGEN
Protagenic Therapeutics, Inc.\new Logo
Develops peptide-based therapeutics for stress-related neuropsychiatric disorders.
United States of America
PTIX
Protara Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm analyzing protein interactions for drug and diagnostic development.
South Korea
468530
PROTEOME SCIENCES PLC Logo
A Contract Research Organization focused on applied proteomics and peptidomics services.
United Kingdom
PRM
PROTHENA CORP PUBLIC LTD CO Logo
Biotechnology company developing therapies for diseases of protein dysregulation.
United States of America
PRTA
PROVEXIS PLC Logo
Develops and licenses functional ingredients for the food and supplement markets.
United Kingdom
PXS
Psomagen, Inc. Logo
A contract lab providing multiomics and data analysis solutions for researchers.
United States of America
950200
Psych Capital Plc Logo
Biopharmaceutical company developing psilocybin-based therapy for anorexia nervosa.
United Kingdom
PSY

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.